Who makes levobupivacaïne 0,5 %?

levobupivacaïne 0,5 % is developed by Nantes University Hospital.

What development phase is levobupivacaïne 0,5 % in?

levobupivacaïne 0,5 % is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

levobupivacaïne 0,5 %

Nantes University Hospital · FDA-approved active Small molecule Quality 1/100

Levobupivacaine 0.5% is a marketed anesthetic developed by Nantes University Hospital, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term patent protection. The primary risk is the potential increase in competition following the 2028 patent expiry.

At a glance

Generic name	levobupivacaïne 0,5 %
Sponsor	Nantes University Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

levobupivacaïne 0,5 % CI brief — competitive landscape report
levobupivacaïne 0,5 % updates RSS · CI watch RSS
Nantes University Hospital portfolio CI